BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 8371582)

  • 21. Low serum levels of tumor necrosis factor and interleukin-1 beta in myelodysplastic syndromes responsive to recombinant erythropoietin.
    Musto P; Matera R; Minervini MM; Checchia-de Ambrosio C; Bodenizza C; Falcone A; Carotenuto M
    Haematologica; 1994; 79(3):265-8. PubMed ID: 7926977
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment of myelodysplastic syndromes with 5q deletion before the lenalidomide era; the GFM experience with EPO and thalidomide.
    Kelaidi C; Park S; Brechignac S; Mannone L; Vey N; Dombret H; Aljassem L; Stamatoullas A; Adès L; Giraudier S; de Botton S; Raynaud S; Lepelley P; Picard F; Leroux G; Daniel MT; Bouscary D; Dreyfus F; Fenaux P;
    Leuk Res; 2008 Jul; 32(7):1049-53. PubMed ID: 18191202
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Recombinant human erythropoietin in the treatment of myelodysplastic syndromes. An interim report.
    Aloe Spiriti MA; Petti MC; Latagliata R; Avvisati G; De Gregoris C; Proia S; Fazi P; Jaalouk G; Mancini M; Spadea A
    Haematologica; 1993; 78(2):123-6. PubMed ID: 8349188
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Recombinant human granulocyte-macrophage colony-stimulating factor plus recombinant human erythropoietin may improve anemia in selected patients with myelodysplastic syndromes.
    Hansen PB; Johnsen HE; Hippe E; Hellström-Lindberg E; Ralfkiaer E
    Am J Hematol; 1993 Dec; 44(4):229-36. PubMed ID: 8237992
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Therapy with recombinant human erythropoietin in patients with myelodysplastic syndromes.
    Stone RM; Bernstein SH; Demetri G; Facklam DP; Arthur K; Andersen J; Aster JC; Kufe D
    Leuk Res; 1994 Oct; 18(10):769-76. PubMed ID: 7934135
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Investigation for the presence of anti-erythropoietin antibodies in patients with myelodysplastic syndromes.
    Voulgari PV; Hatzimichael EC; Tsiara S; Tzallas C; Drosos AA; Bourantas KL
    Eur J Haematol; 2001 Jan; 66(1):31-6. PubMed ID: 11168505
    [TBL] [Abstract][Full Text] [Related]  

  • 27. High-dose recombinant human erythropoietin for treatment of anemia in myelodysplastic syndromes and paroxysmal nocturnal hemoglobinuria: a pilot study.
    Stebler C; Tichelli A; Dazzi H; Gratwohl A; Nissen C; Speck B
    Exp Hematol; 1990 Dec; 18(11):1204-8. PubMed ID: 2226680
    [TBL] [Abstract][Full Text] [Related]  

  • 28. High-dose (40,000 IU twice/week) alpha recombinant human erythropoietin as single agent in low/intermediate risk myelodysplastic syndromes: a retrospective investigation on 133 patients treated in a single institution.
    Azzarà A; Carulli G; Galimberti S; Baratè C; Fazzi R; Cervetti G; Petrini M
    Am J Hematol; 2011 Sep; 86(9):762-7. PubMed ID: 21850658
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Improvement of anemia by recombinant erythropoietin in patients with myelodysplastic syndromes and aplastic anemia.
    Bessho M; Jinnai I; Matsuda A; Saito M; Hirashima K
    Int J Cell Cloning; 1990 Nov; 8(6):445-58. PubMed ID: 2273298
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Clinical efficacy analysis of recombinant human erythropoietin in the treatment of lower-risk myelodysplastic syndromes].
    Zhang H; Qin T; Xu Z; Fang L; Pan L; Hu N; Qu S; Zhang Y; Xiao Z
    Zhonghua Xue Ye Xue Za Zhi; 2014 Jan; 35(1):18-23. PubMed ID: 24602726
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy of recombinant human erythropoietin in the treatment of refractory anemias without excess of blasts in myelodysplastic syndromes.
    Isnard F; Najman A; Jaar B; Fenaux P; Baillou C; Khoury E; Labopin M; Laporte JP; Woler M; Gorin NC
    Leuk Lymphoma; 1994 Jan; 12(3-4):307-14. PubMed ID: 8167562
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-term follow-up of myelodysplastic syndrome patients with moderate/severe anaemia receiving human recombinant erythropoietin + 13-cis-retinoic acid and dihydroxylated vitamin D3: independent positive impact of erythroid response on survival.
    Crisà E; Foli C; Passera R; Darbesio A; Garvey KB; Boccadoro M; Ferrero D
    Br J Haematol; 2012 Jul; 158(1):99-107. PubMed ID: 22571649
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Human recombinant erythropoietin in the treatment of myelodysplastic syndromes anemia. Meta-analytic study].
    Rodríguez JN; Diéguez JC; Muñiz R; Martino ML; Fernández-Jurado A; Amian A; Cañavate M; Prados D
    Sangre (Barc); 1994 Dec; 39(6):435-9. PubMed ID: 7855695
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Recombinant human erythropoietin in patients with myelodysplastic syndrome and myelofibrosis.
    Mohr B; Herrmann R; Huhn D
    Acta Haematol; 1993; 90(2):65-70. PubMed ID: 8285020
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy of erythropoietin in the myelodysplastic syndromes: a meta-analysis of 205 patients from 17 studies.
    Hellström-Lindberg E
    Br J Haematol; 1995 Jan; 89(1):67-71. PubMed ID: 7833279
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Measurement of serum cytokine levels in patients with myelodysplastic syndromes.
    Verhoef GE; De Schouwer P; Ceuppens JL; Van Damme J; Goossens W; Boogaerts MA
    Leukemia; 1992 Dec; 6(12):1268-72. PubMed ID: 1280751
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Serum erythropoietin and creatinine concentrations as predictive factors for response to recombinant human erythropoietin treatment in anaemic tumour patients on chemotherapy.
    Fjornes T; Wiedemann GJ; Sack K; Jelkmann W
    Oncol Rep; 1998; 5(1):81-6. PubMed ID: 9458299
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In vitro studies of erythropoietin-dependent regulation of erythropoiesis in myelodysplastic syndromes.
    Merchav S; Nielsen OJ; Rosenbaum H; Sharon R; Brenner B; Tatarsky I; Scigalla P; Wieczorek L
    Leukemia; 1990 Nov; 4(11):771-4. PubMed ID: 2232891
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacologic doses of recombinant human erythropoietin in the treatment of myelodysplastic syndromes.
    Stein RS; Abels RI; Krantz SB
    Blood; 1991 Oct; 78(7):1658-63. PubMed ID: 1912554
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Recombinant human erythropoietin (rHuEPO) for treatment of myelodysplastic syndrome.
    Zeigler ZR; Jones D; Rosenfeld CS; Shadduck RK
    Stem Cells; 1993 Jan; 11(1):49-55. PubMed ID: 8457781
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.